Immedica Pharma AB

Company snapshot

About Immedica Pharma Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Welcome to the Immedica social media channels The Immedica social channels are set up to share news, updates, and company happenings with all visitors. Please note that postings by other visitors do not necessar

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Immedica Pharma AB. Not investment advice.

• What is Immedica Pharma AB?

  Immedica Pharma AB is a pharma organization headquartered in Stockholm, SE. Primary therapeutic focus areas include Arginase 1 deficiency (ARG1-D). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalT

• Is Immedica Pharma AB publicly traded?

  Immedica Pharma AB appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Immedica Pharma AB develop or market?

  We link 4 drug profile(s) where Immedica Pharma AB is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/immedica-pharma-ab#company-drugs.

• What are the latest developments for Immedica Pharma AB?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Immedica Pharma AB focus on?

  Immedica Pharma AB focuses on Arginase 1 deficiency (ARG1-D) based on our analysis of their pipeline programs and drug development activities.